


Editorial

# Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus



Emily A. Smitherman<sup>1</sup>  and Randy Q. Cron<sup>1</sup> 

Macrophage activation syndrome (MAS) is a potentially life-threatening condition of hyperinflammation that can be secondary to an underlying chronic rheumatic condition, commonly systemic juvenile idiopathic arthritis (sJIA) but also childhood-onset systemic lupus erythematosus (cSLE). MAS is characterized by excessive activation of T lymphocytes and macrophages that lead to overproduction of cytokines and results in cytopenia, liver dysfunction, and coagulopathy<sup>1</sup>. It is critical to recognize MAS early in order to initiate the appropriate treatment quickly and prevent morbidity and mortality. However, in MAS secondary to rheumatic conditions, it can be difficult to distinguish MAS from active disease due to overlapping inflammatory features. Criteria to diagnose MAS in children with sJIA have been developed and initially validated<sup>2,3</sup>. Guidelines to diagnose MAS in children with SLE have been previously proposed though not further validated<sup>4</sup>. In the current issue of *The Journal of Rheumatology*, Gerstein and colleagues present novel criteria to discriminate MAS from active disease in patients with newly diagnosed cSLE, especially in those who are hospitalized, and compare the performance of their developed criteria to existing criteria<sup>5</sup>.

In this report, the authors retrospectively reviewed hospitalizations of patients newly diagnosed with cSLE at a single center and divided patients into 2 cohorts from 2003–2007 and 2008–2013. They selected patients who were febrile, with no prior corticosteroid exposure, and with no evidence of infection. These criteria identified 34 patients in the 2003–2007 cohort and 41 patients in the 2008–2013 cohort. The diagnosis of MAS

was based on expert opinion of the treating clinician during the hospital admission and validated by an independent investigator. Out of the total cohort of febrile, hospitalized patients with new diagnosis of cSLE, 26% of patients had a diagnosis of MAS. While there were no statistically significant differences based on clinical features between the 2 patient groups with and without MAS, use of the recursive partitioning technique allowed for identification of cutoff laboratory values to differentiate patients with MAS from those without MAS. The team developed 3 sets of criteria utilizing data from each subcohort and the total cohort. Interestingly, hyperferritinemia and cytopenia—specifically leukopenia and lymphopenia—were identified as the key features to distinguish MAS from active cSLE disease. The first set of criteria included ferritin  $\geq 669$   $\mu\text{g/L}$ . The second set of criteria included (1) ferritin  $\geq 1107$   $\mu\text{g/L}$ , and (2) lymphocyte count  $< 0.72 \times 10^3/\text{mm}^3$ . The third and best-fitting model using the total cohort included (1) ferritin  $\geq 669$   $\mu\text{g/L}$  and (2) white blood cells  $< 2.25 \times 10^3/\text{mm}^3$ .

This work provides a critical step forward in the goal to improve our identification of patients with MAS complicating cSLE, especially in newly diagnosed, hospitalized patients. By applying existing hemophagocytic lymphohistiocytosis (HLH) and MAS criteria to the current dataset, the authors demonstrated improved performance of their newly developed criteria for MAS in cSLE. The 2004 HLH diagnostic guidelines<sup>6</sup> had low sensitivity of 47% when applied to a subset of the patients who had a bone marrow aspirate/biopsy performed. While the specificity was high at 93%, we agree with the authors that reliance on a procedure that is difficult to complete in critically ill patients or other specialized testing with limited availability could result in a delay of diagnosis. Preliminary criteria for MAS in cSLE proposed by the PReS Lupus Working Group<sup>4</sup> demonstrated 100% sensitivity but only 25% specificity, likely due to lower laboratory threshold values. The authors suggest a potential algorithm that combines both the PReS Lupus Working

<sup>1</sup>E.A. Smitherman, MD, MS, Assistant Professor, R.Q. Cron, MD, PhD, Professor, Division of Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

The authors report no commercial financial disclosures related to this work.

Address correspondence to Dr. E.A. Smitherman, The Children's Hospital, CPP N G10, 1600 7th Ave S, Birmingham, AL 35223-1711, USA. Email: Emily.Smitherman@peds.uab.edu.

See Predicting MAS in cSLE, page xxx

Group criteria and their newly defined criteria to improve identification of MAS in cSLE. Additional validation with an independent patient cohort could help further determine optimal application of these criteria for use in routine clinical care.

Notably, the authors' findings are consistent with existing criteria for MAS in sJIA, especially the ferritin threshold of 600–700 µg/L. Both the current report and previous work in sJIA use clinician diagnosis as the gold standard; therefore, there may be bias in how these criteria are developed with clinicians using existing criteria in their diagnostic assessment. However, the authors of the current report also incorporated response to therapy in their MAS diagnosis verification procedure to increase confidence in the presence of MAS. While there was a high prevalence of MAS observed in 26% of the patients in this cohort, it is possible that MAS still remains underdiagnosed in cSLE, as has been observed in sJIA<sup>7,8</sup>. Use of a more objective gold standard to diagnose in a prospective manner is challenging to study due to the rarity of these conditions.

It is also interesting that while the authors retrospectively searched for hospitalizations within 12 months of cSLE diagnosis, all cases of MAS occurred within 30 days of cSLE diagnosis. This is consistent with repeated reports in the literature of MAS occurring with the initial presentation of cSLE<sup>9,10</sup>. Therefore, we should have a high suspicion of MAS in patients with newly diagnosed cSLE, especially if febrile and hospitalized. A previous comparison of MAS between cSLE and sJIA demonstrated lower ferritin levels in cSLE compared to sJIA, but more frequent multiorgan failure<sup>11</sup>. Data from US hospitalized children showed a delay in time to first ferritin level in patients with cSLE compared to sJIA<sup>12</sup>. While there is evidence that treating cSLE disease activity is often sufficient to also treat secondary MAS due to almost universal use of methylprednisolone in cSLE induction, many patients require additional therapy, including anakinra, calcineurin inhibitors, and intravenous Ig, to more specifically target MAS<sup>13</sup>. Moreover, higher mortality across cSLE and sJIA patients with MAS was observed when referred to a tertiary care center ≥ 15 days after the onset of MAS symptoms<sup>14</sup>. Therefore, early recognition is critical to initiate appropriate intervention and prevent adverse outcomes.

In addition to improving pediatric rheumatologist awareness of MAS in cSLE, it is also important to educate other clinicians on the prevalence and significance of these conditions. Further, working to implement systematic changes to screening procedures would improve the reliability of MAS evaluation in patients with cSLE and prevent diagnostic delay. Studies by Halyabar, *et al* and Hoyt, *et al* have demonstrated that developing and implementing a standard approach to the management of patients with fever and ferritin > 500 µg/L across disciplines<sup>15</sup> decreased time to MAS diagnosis from 8.4 to 2.8 days and decreased mortality from 25% to 6.7%<sup>16</sup>. This provides support that serum ferritin could serve as an important screening tool in hospitalized febrile patients to achieve earlier recognition and intervention on MAS. In fact, ferritin ≥ 627 µg/L has been shown to be 89% specific with 95% sensitivity to identify patients with MAS compared to all febrile hospitalized patients<sup>17</sup>.

In summary, the findings of Gerstein and colleagues is an important contribution to the field by providing additional tools to recognize MAS as a complication of newly diagnosed cSLE and to distinguish MAS from active disease. As fever and pancytopenia are frequently present during cSLE presentation, the addition of serum ferritin to the evaluation may help to identify MAS early during hospitalization and save lives. Continued work in this area is needed to further validate and reliably implement a screening protocol based on identified criteria.

## REFERENCES

1. Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. *Paediatr Drugs* 2020;22:29-44.
2. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. *Arthritis Rheumatol* 2016;68:566-76.
3. Minoia F, Bovis F, Davi S, Horne A, Fischbach M, Frosch M, et al; Pediatric Rheumatology International Trials Organization, the Childhood Arthritis & Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group and the Histiocyte Society. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. *Ann Rheum Dis* 2019;78:1357-62.
4. Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al; Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. *Arthritis Rheum* 2009;60:3388-99.
5. Gerstein M, Borgia RE, Dominguez D, Feldman BM, Liao F, Levy D, et al. Predicting macrophage activation syndrome (MAS) in childhood-onset systemic lupus erythematosus (cSLE) patients at diagnosis. *J Rheumatol* 2021;48:xxxxx.
6. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007;48:124-31.
7. Blesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. *Arthritis Rheum* 2007;56:965-71.
8. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. *J Rheumatol* 2007;34:1133-8.
9. Zulian F, Piccinini P, Martini G, Jorini M, de Benedictis FM. Macrophage activation syndrome as trigger event for systemic lupus erythematosus in children. *J Paediatr Child Health* 2009;45:621-2.
10. Vilaiyuk S, Sirachainan N, Wanitkun S, Pirojsakul K, Vaewpanich J. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. *Clin Rheumatol* 2013;32:899-904.

11. Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? *Lupus* 2007;16:587-92.
12. Bennett TD, Fluchel M, Hersh AO, Hayward KN, Hersh AL, Brogan TV, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. *Arthritis Rheum* 2012;64:4135-42.
13. Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. *Arthritis Rheumatol* 2018;70:616-24.
14. Aytac S, Batu ED, Unal S, Bilginer Y, Cetin M, Tuncer M, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. *Rheumatol Int* 2016;36:1421-9.
15. Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. *Pediatr Rheumatol Online J* 2019;17:7.
16. Hoyt K, Halyabar O, Han J, Case SM, Chang MH, Platt CD, et al. Outcomes of an evidence based guideline for the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome [abstract]. *Arthritis Rheumatol* 2020;72.
17. Elosily EMA, Minoia F, Crayne CB, Beukelman T, Ravelli A, Cron RQ. Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. *ACR Open Rheumatol* 2019;1:345-9.